MASSAIA, Massimo Giovanni Stefano
 Distribuzione geografica
Continente #
NA - Nord America 8.960
EU - Europa 7.327
AS - Asia 3.286
AF - Africa 158
SA - Sud America 66
OC - Oceania 50
Continente sconosciuto - Info sul continente non disponibili 29
Totale 19.876
Nazione #
US - Stati Uniti d'America 8.793
CN - Cina 2.189
DE - Germania 1.089
IT - Italia 1.054
SE - Svezia 1.004
IE - Irlanda 877
UA - Ucraina 771
FR - Francia 641
FI - Finlandia 468
AT - Austria 433
KR - Corea 368
GB - Regno Unito 306
PL - Polonia 227
IN - India 170
VN - Vietnam 158
SG - Singapore 157
CA - Canada 141
SN - Senegal 112
JP - Giappone 63
NL - Olanda 63
GR - Grecia 60
RU - Federazione Russa 59
DK - Danimarca 58
AU - Australia 46
BE - Belgio 41
BR - Brasile 32
ES - Italia 30
HK - Hong Kong 29
EU - Europa 26
BY - Bielorussia 25
TR - Turchia 24
CH - Svizzera 23
UZ - Uzbekistan 22
TW - Taiwan 21
MX - Messico 20
PT - Portogallo 20
ZA - Sudafrica 16
CL - Cile 13
NO - Norvegia 13
TH - Thailandia 13
HU - Ungheria 12
IR - Iran 12
MU - Mauritius 12
RO - Romania 12
SA - Arabia Saudita 11
ID - Indonesia 10
CO - Colombia 9
RS - Serbia 9
CZ - Repubblica Ceca 8
MK - Macedonia 8
EG - Egitto 7
IL - Israele 7
LU - Lussemburgo 6
PK - Pakistan 6
AR - Argentina 5
PE - Perù 5
DZ - Algeria 4
NZ - Nuova Zelanda 4
SY - Repubblica araba siriana 4
AE - Emirati Arabi Uniti 3
AM - Armenia 3
HR - Croazia 3
KZ - Kazakistan 3
MA - Marocco 3
PH - Filippine 3
AP - ???statistics.table.value.countryCode.AP??? 2
CU - Cuba 2
HN - Honduras 2
IQ - Iraq 2
LV - Lettonia 2
NG - Nigeria 2
SI - Slovenia 2
A1 - Anonimo 1
BD - Bangladesh 1
BG - Bulgaria 1
BW - Botswana 1
CR - Costa Rica 1
CY - Cipro 1
EC - Ecuador 1
GI - Gibilterra 1
KH - Cambogia 1
LK - Sri Lanka 1
MD - Moldavia 1
MO - Macao, regione amministrativa speciale della Cina 1
NP - Nepal 1
OM - Oman 1
PA - Panama 1
QA - Qatar 1
UY - Uruguay 1
ZW - Zimbabwe 1
Totale 19.876
Città #
Beijing 1.702
Chandler 1.226
Dublin 874
Jacksonville 521
Ashburn 488
Houston 447
Vienna 430
Ann Arbor 410
Villeurbanne 355
Medford 322
Nyköping 318
Fairfield 298
Dearborn 290
Princeton 281
Wilmington 264
Torino 226
Warsaw 215
Woodbridge 191
San Mateo 182
Seattle 136
Redwood City 125
Milan 119
Fremont 117
Cambridge 106
Pisa 96
Dong Ket 93
Turin 90
Boston 82
Boardman 79
Toronto 67
New York 66
Washington 66
Munich 61
Singapore 61
Shanghai 58
Düsseldorf 44
Pune 43
Hefei 42
Rome 41
Nanjing 40
Norwalk 40
Falls Church 36
Verona 36
Nürnberg 35
Mountain View 32
Guangzhou 30
Phoenix 29
Brussels 28
Hangzhou 28
Los Angeles 27
Tokyo 27
Lachine 26
Paris 26
Kunming 25
Chengdu 24
San Diego 24
Raritan 20
Lappeenranta 18
Jinan 17
Philadelphia 16
Hebei 15
Helsinki 15
Taipei 15
Chennai 14
Duncan 14
Nanchang 14
Dallas 13
Florence 13
Changsha 12
Des Moines 12
Ottawa 12
Rotterdam 12
Wuhan 12
London 11
San Jose 11
Shenyang 11
Bologna 10
Central District 10
Fuzhou 10
Hyderabad 10
Marseille 10
Padova 10
Piemonte 10
Seoul 10
Amsterdam 9
Den Haag 9
Leawood 9
Mexico 9
Mumbai 9
Palermo 9
Zhengzhou 9
Bogotá 8
Lisbon 8
Mcallen 8
Provo 8
Silver Spring 8
Upper Marlboro 8
Bengaluru 7
Chongqing 7
Detroit 7
Totale 11.634
Nome #
Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients 441
Stem cell transplantation in multiple myeloma and other plasma cell disorders (report from an EBMT preceptorship meeting) 413
A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia 325
Clinicopathologic spectrum of cutaneous diseases in patients with hematologic malignancies with or without allogeneic bone marrow transplantation: an observational cohort study in 101 patients. 294
REGULATION OF HIF-1 alpha IN TP53 DISRUPTED CHRONIC LYMPHOCYTIC LEUKEMIA CELLS AND ITS POTENTIAL ROLE AS A THERAPEUTIC TARGET 278
IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells 270
Chicago 2014 - 30 years of γδ T cells 242
The ATP-binding cassette transporter A1 regulates phosphoantigen release and Vγ9Vδ2 T cell activation by dendritic cells 242
Management of multiple myeloma and related-disorders: guidelines from the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES) and Italian Group for Bone Marrow Transplantation (GITMO) 237
The Defective Proliferation of Vgamma9Vdelta2 T Cells to Zoledronic Acid In Chronic Lymphocytic Leukemia (CLL) Is a Powerful Time to First Treatment (TFT) Predictor Associated with the IGHV Mutational Status. 190
Anergic bone marrow Vγ9Vδ2 T cells as early and long-lasting markers of PD-1-targetable microenvironment-induced immune suppression in human myeloma 189
Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile 176
Unmutated IGHV1-69/D3-16/J3 Stereotyped HCDR3 Rearrangements (Subset 6) Are Associated with Indolent Disease Course and Have Outcome Independent of Mutational Status In Early Stage CLL (Rai 0) 172
Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding 169
Increasing intratumor C/EBP-β LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer 165
Zoledronic Acid Restores Doxorubicin Chemosensitivity and Immunogenic Cell Death in Multidrug-Resistant Human Cancer Cells 154
Simvastatin and downstream inhibitors circumvent constitutive and stromal cell-induced resistance to doxorubicin in IGHV unmutated CLL cells 153
null 148
Humoral immune responses toward tumor-derived antigens in previously untreated patients with chronic lymphocytic leukemia 132
Amplification of T cell activation induced by CD73 (ecto-5' nucleotidase) engagement. 130
HIF-1α is overexpressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia 130
Final Report of Bendamustine and Alemtuzumab (BEN CAM) Combination in Relapsed and Refractory Chronic Lymphocytic Leukemia 128
Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma. 128
A phase II multi-center trial of pentostatin plus cyclophosphamide with ofatumumab in older previously untreated chronic lymphocytic leukemia patients 125
ABCA1, apoA-I, and BTN3A1: A Legitimate ménage à trois in dendritic cells 125
Identification of Novel Tumor-Associated Antigens in Chronic Lymphocytic Leukemia (CLL) by Serological Proteome Analysis (SERPA) 119
Effective anti-tumor immunomodulatory properties of zoledronic acid 116
Zoledronic acid repolarizes tumor-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway 115
The Mevalonate Pathway and Downstream Signal Transducers As Therapeutic Targets to Overcome Multidrug Resistance in Chronic Lymphocytic Leukemia (CLL) 112
Immunoglobulin variable heavy-chain (Ig Vh) mutational status and tumor microenvironment interactions in B-cell chronic lymphocytic leukaemia 112
Vγ9Vδ2 T cells as strategic weapons to improve the potency of immune checkpoint blockade and immune interventions in human myeloma 112
Vγ9Vδ2 T Cells in the Bone Marrow of Myeloma Patients: A Paradigm of Microenvironment-Induced Immune Suppression 111
TELOMERES SHORTEN DURING CHRONIC LYMPHOCYTIC LEUKEMIA(CLL) EVOLUTION: AN ANALYSIS ON 88 CASES 111
Multiple myeloma: altered CD4/CD8 ratio in bone marrow. 108
Advances in biology of multiple myeloma: cell kinetics, molecular biology and immunology. 107
Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: Correlation with biologically-based risk stratification 107
Low Dose TBI Based Nonmyeloablative Conditionings for Allografting in Multiple Myeloma: Impact of Disease Status at Transplant. 106
A PROSPECTIVE PHASE II STUDY ON TANDEM AUTOGRAFTING-ONMYELOABLATIVE ALLOGRAFTING FOR NEWLY DIAGNOSED MULTIPLE MYELOMA: FINAL RESULTS OF A MULTICENTER GITMO (GRUPPO ITALIANO TRAPIANTO MIDOLLO OSSEO) PROTOCOL 106
CD157 reduces acutemyeloid leukemia cell sensitivity tocytarabine through upregulation of MCL-1 anti-apoptotic protein 106
IDENTIFICATION BY SEROLOGICAL PROTEOME ANALYSIS (SERPA) OF TUMOR-ASSOCIATED ANTIGENS ELICITING ANTIBODY RESPONSES IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) 104
The Mevalonate Pathway As a Metabolic Target to Circumvent Multidrug-Resistance in Chronic Lymphocytic Leukemia Cells 103
The tryptophan metabolism in the immune dysregulation of multiple myeloma 102
Phenotypic and Functional Features of V{gamma}9/V{delta}2 T Cells in Chronic Lymphocytic Leukemia Are Strongly Correlated with the Mutational Status of the Immunoglobulin Heavy Chain Variable Region (IgVH) and Metabolic Activity of the Mevalonate Pathway in Tumor Cells 100
Refractory cytopenia with multilinear dysplasia (RCMD) in patient with Fanconi anaemia 99
Identification and functional characterization of tumor specific antibody responses in chronic lymphocytic leukemia 99
Progressive Telomere Shortening Is Part of the Natural History of Chronic Lymphocytic Leukemia (CLL) and Impacts Clinical Outcom 98
CD157 REGULATES THE SENSITIVITY OF ACUTE MYELOID LEUKEMIA CELLS TO CHEMOTHERAPY BY MODULATING THE APOPTOTIC RESPONSE 98
Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy. 98
Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy 97
Is there a role for allografting in myeloma ?: an update of a comparative study 97
Role of PD-1/PD-L1 axis in the immune paresis of bone marrow Vγ9Vδ2 T cells in multiple myeloma 97
THE LOCAL MICROENVIRONMENT PLAYS A DIFFERENT ROLE IN THE SURVIVAL OF TUMOR CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA WITH MUTATED AND UNMUTATED IMMUNOGLOBULIN (IG) VH GENES 96
IDENTIFICATION AND FUNCTIONAL CHARACTERIZATION OF ANTIBODY IMMUNE RESPONSES ELICITED BY SELF ANTIGENS IN CHRONIC LYMPHOCYTIC LEUKEMIA 96
Regulation of HIF-1α in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role as a Therapeutic Target 94
Targeting the mevalonate pathway and downstream signaling pathways as a strategy to circumvent multidrug-resistance in CLL cells 92
The immune suppressive tumor microenvironment in multiple myeloma: The contribution of myeloid-derived suppressor cells 91
[Idiotypic study of human myeloma] 91
Accelerated activity of the mevalonate pathway supports the immune escape and multidrug-resistance phenotype of IGHV unmutated chronic lymphocytic leukemia cells 90
Molecular prediction of durable remission after first-line fludarabinecyclophosphamide-rituximab in chronic lymphocytic leukemia 90
PROGRESSIVE TELOMERE SHORTENING DURING THE NATURAL HISTORY OF CHRONIC LYMPHOCYTIC LEUKEMIA 90
Serological Proteome Analysis (SERPA) as a tool for the identification of novel tumor antigens in chronic lymphocytic leukemia (CLL) 90
Cytobiological studies in multiple myeloma. 89
Lack of correlation between plasma cell thymidine labelling index and serum beta-2-microglobulin in monoclonal gammopathies. 89
Telomere Length Is An Independent Predictor of Survival, Treatment Requirement and Richter’s Syndrome Transformation in Chronic Lymphocytic Leukemia 89
A Score-Based Approach to18F-FDG PET Images as a Tool to Describe Metabolic Predictors of Myocardial Doxorubicin Susceptibility 89
IGHV Unmutated Chronic Lymphocytic Leukemia (CLL) B Cells Are More Susceptible to Spontaneous Apoptosis Than Mutated CLL B Cells and Are Subject to the Anti-Apoptotic Effect of Environmental Signals 88
Zoledronic acid restores doxorubicin chemosensitivity and immunogenic cell death in multidrug-resistant human cancer cells 88
IMPACT OF THE MEVALONATE PATHWAY AND HIF/PGP AXIS IN MODULATING MULTIDRUG-RESISTANCE IN UNMUTATED CLL CELLS 88
The metabolism of mevalonate as a signaling pathway influencing tumor-host interactions and disease progression in chronic lymphocytic leukemia (CLL) 88
Telomere lenght measurement in the clinically oriented research setting: a comparison between Southern blot (SB), real time quantitative PCR (RQ-PCR) and FLOW-FISH (FF) 87
Telomere length is an independent predictor of survival, treatment requirement and Richter’s syndrome transformation in chronic lymphocytic leukemia 87
Difference in polyamine transport in human B and T lymphocytes. 86
Biochemical evidence for the presence of abnormal B lymphocytes in the peripheral blood of multiple myeloma patients. 86
Multiple myeloma: beta-2-microglobulin is not a useful follow-up parameter. 84
Serological proteome analysis (SERPA) as a tool for the identification of tumor antigens capable of eliciting immune responses in chronic lymphocytic leukemia (CLL) 84
Progressive telomere shortening occurs during the natural history of chronic lymphocytic leukemia (CLL) and associates to outcome 84
Early CPAP prevents evolution of acute lung injury in patients with hematologic malignancy. 84
Cyclosporin A and dipyridamole: an effective combination against the generation of cytotoxic T lymphocytes (CTL). 83
Differential Effects of Microenvironmental Elements On Tumor Cells Survival in Chronic Lymphocytic Leukemia Patient Subsets with Good or Poor Prognosis 83
Expression of telomeric proteins in chronic lymphocytic leukemia (CLL) 83
Anticancer innovative therapy: Highlights from the ninth annual meeting 83
Identification by serological proteome analysis (SERPA) of novel tumor associated antigens in chronic lymphocytic leukemia (CLL) 82
TWO DOSE-INTENIVE MELPHALAN REGIMENS (100 MG/M2 VERSUS 200 MG/M2) IN MULTIPLE MYELOMA PATIENTS 81
Dendritic Cells Can Be Primed to Concurrently Activate Both Unconventional Gamma/delta and Conventional alpha/beta T Cells 81
Defective interleukin-2 induction of lymphokine-activated killer (LAK) activity in peripheral blood T lymphocytes of patients with monoclonal gammopathies. 80
Monoclonal immunoglobulin gene rearrangement in peripheral lymphocytes of a patient with multiple myeloma. 80
Comparison of purine degradative enzymes and terminal deoxynucleotidyl transferase in T cell leukaemias and in normal thymic and post-thymic T cells. 80
Changes in SRBC binding capacity and T-surface antigen expression on human peripheral blood lymphocytes stimulated by 12-0-tetradecanoilphorbol-13-acetate (TPA). 80
null 80
Activated idiotype-reactive cells in suppressor/cytotoxic subpopulations of monoclonal gammopathies:correlation with diagnosis and disease status. 80
Identification by serological proteome analysis (SERPA) of tumor-associated antigens eliciting antibody-responses in chronic lymphocytic leukemia 80
B cells from chronic lymphocytic leukemia (CLL) patients are strong inducers of proliferation and major histocompatibility complex (MHC)-unrestricted [natural killer (NK)-like] cytotoxicity in normal T-lymphocytes. 80
BENDAMUSTINE AND ALEMTUZUMAB (BEN CAM) COMBINATION IN RELAPSED AND REFRACTORY CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL): PHASE I SAFETY PROFILE RESULTS OF THE ITALIAN TRIAL 79
SEROLOGICAL PROTEOME ANALYSIS (SERPA) FOR THE IDENTIFICATION OF TUMOR-ASSOCIATED ANTIGENS ELICITING ANTIBODY-RESPONSES IN CHRONIC LYMPHOCYTIC LEUKEMIA 79
[Prognostic factors in multiple myeloma] 78
CD38 stimulation lowers the activation threshold and enhances the alloreactivity of cord blood T cells by activating the phosphatidylinositol 3-kinase pathway and inducing CD73 expression. 78
Dysfunctional Vγ9Vδ2 T cells are negative prognosticators and markers of dysregulated mevalonate pathway activity in chronic lymphocytic leukemia cells. 78
The bone marrow of myeloma patients is steadily inhabited by a normal-sized pool of functional regulatory T cells irrespective of the disease status. 78
Effector gammadelta T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma 77
Bendamustine and subcutaneous Alemtuzumab combination is an effective treatment in relapsed/refractory chronic lymphocytic leukemia patients. 77
Totale 12.046
Categoria #
all - tutte 57.495
article - articoli 0
book - libri 0
conference - conferenze 21.402
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 78.897


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019185 0 0 0 0 0 0 0 0 0 0 0 185
2019/20202.601 79 117 147 250 202 461 360 152 221 252 207 153
2020/20212.693 271 155 170 156 291 125 175 134 321 209 377 309
2021/20223.011 108 89 91 218 123 57 463 159 104 326 648 625
2022/20233.960 415 321 93 347 353 997 312 255 415 132 204 116
2023/20241.726 225 363 120 101 110 344 53 104 15 104 132 55
Totale 20.714